Plain-English translation of NCT04410796 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether people with advanced lung cancer carrying an EGFR mutation benefit from taking alone or combined with chemotherapy drugs. is already standard treatment for this type of cancer, but researchers want to see if adding chemotherapy makes it work even better. You would be randomly assigned to one of the two treatment groups.
Some patients continue to have signs of cancer (detected through blood tests) even after starting this medication, which suggests the cancer may not be fully controlled. This trial is testing whether adding chemotherapy can help overcome this and improve survival.
You likely qualify if…
You likely don't qualify if…
You would first take the medication alone for 3 weeks to see how your cancer responds. Then, if cancer cells are still detected in your blood, you would be randomly assigned to either continue the medication alone or add chemotherapy infusions every 3 weeks for 4 cycles, followed by ongoing treatment. You would have regular clinic visits, blood tests, and imaging scans to monitor your progress, and you would need to keep a pill diary starting at week 9 of treatment.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States